Rinvoq shown an effective in treating crohn’s & ulcerative colitis

Rinvoq shown an effective in treating crohn’s & ulcerative colitis

Rinvoq (upadacitinib) was effective in treating Crohn’s disease (CD) and ulcerative colitis (UC), according to recent research. AbbVie executives presented the study results at the American College of Gastroenterology (ACG)’s Annual Scientific Meeting, held...
Impact of intensive drug therapy on Crohn’s Disease patients

Impact of intensive drug therapy on Crohn’s Disease patients

Intensive drug therapy improved symptoms, stricture-associated inflammation and stricture morphology among patients with Crohn’s disease, according to research published in The Lancet Gastroenterology & Hepatology1 . Julien D. Schulberg, MBBS, of the...
First Phase 3 Induction Study on Upadacitinib (RINVOQ®)

First Phase 3 Induction Study on Upadacitinib (RINVOQ®)

AbbVie (NYSE: ABBV) announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remissiona,b and endoscopic responsec at week 12.1 The U-EXCEED study enrolled...